The EURAS project received over 8 million euros funding from the Health Cluster of the Horizon Europe Research and Innovation Programme
Rare neurodevelopmental disorders of the Ras pathway continue to evade effective treatment. The EURAS consortium has been awarded over 8 million euros from the Health Cluster of the Horizon Europe Research and Innovation Programme to develop new effective therapies and establish a framework for early, accurate diagnosis of neurological symptoms in a specific group of RASopathies (cardio-facio-cutaneous syndrome, Costello syndrome and SYNGAP1-related encephalopathy).
– The consortium will identify disease signatures, develop new and use existing disease models, identify and validate new therapeutic approaches and brain delivery systems and, with patient organisations from 13 countries, establish a patient registry for stratification and evaluation of therapeutic approaches, says group leader and Senior Research Fellow Michael Courtney from Turku Bioscience Centre, University of Turku. > Keep reading
> Read more about the consortium
There is a position available on this project, application deadline is on 19 June 2023.